Evotec

OverviewSuggest Edit

Evotec is a drug discovery alliance and development partnership company. It provides pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capital firms with drug discovery solutions in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company specializes in the areas of neuroscience, diabetes, complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis.

TypePublic
Founded1993
HQHamburg, DE
Websiteevotec.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Mar 2022)4,354(+4%)
Job Openings451
Revenue (FY, 2021)€618 M(+24%)
Share Price (Jun 2022)€23.6(-2%)
Cybersecurity ratingCMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Evotec

Werner Lanthaler

Werner Lanthaler

Chief Executive Officer
Craig Johnstone

Craig Johnstone

Chief Operating Officer
Enno Spillner

Enno Spillner

Chief Financial Officer
Cord Dohrmann

Cord Dohrmann

Chief Scientific Officer
Volker Braun

Volker Braun

SVP, Head of Global Investor Relations & ESG
Matthias Evers

Matthias Evers

Chief Business Officer
Show more

Evotec Office Locations

Evotec has offices in Hamburg, Göttingen, Köln, Neuried and in 9 other locations
Hamburg, DE (HQ)
Essener Bogen 7
Göttingen, DE
Marie-Curie-Straße 7
Köln, DE
Nattermannallee 1/Gebäude S20
Neuried, DE
Anna-Sigmund-Str. 5
Orth an der Donau, AT
Uferstraße 15
Lyon, FR
40 Avenue Tony Garnier
Show all (13)

Evotec Financials and Metrics

Evotec Revenue

Evotec's revenue was reported to be €618.03 m in FY, 2021
EUR

Revenue (Q1, 2022)

164.7m

Gross profit (Q1, 2022)

50.8m

Net income (Q1, 2022)

(73.2m)

EBITDA (Q1, 2022)

(66.4m)

EBIT (Q1, 2022)

(66.1m)

Market capitalization (29-Jun-2022)

4.1b

Closing stock price (29-Jun-2022)

23.6

Cash (31-Mar-2022)

660.5m

EV

4.0b
Evotec's current market capitalization is €4.1 b.
Annual
EURFY, 2018FY, 2019FY, 2020FY, 2021

Revenue

375.4m446.4m500.9m618.0m

Cost of goods sold

(232.1m)(264.7m)(303.1m)(400.9m)

Gross profit

214.6m258.2m270.0m290.6m

R&D expense

(35.6m)(58.4m)(63.9m)(72.2m)
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Revenue

103.8m103.2m114.3m119.4m111.6m129.4m133.1m138.2m159.7m164.7m

Cost of goods sold

(61.3m)(59.7m)(66.6m)(71.5m)(78.0m)(121.7m)(83.3m)(102.6m)(145.6m)(132.4m)

Gross profit

61.0m61.0m65.8m64.8m51.7m27.2m66.1m55.5m31.6m50.8m

R&D expense

(14.4m)(14.9m)(12.0m)(15.1m)(14.7m)(16.3m)(18.5m)(17.0m)(18.0m)(18.1m)
Annual
EURFY, 2018FY, 2019FY, 2020FY, 2021

Cash

109.1m277.0m422.6m699.3m

Accounts Receivable

45.9m82.3m79.0m132.1m

Prepaid Expenses

22.3m31.9m31.0m42.6m

Inventories

5.7m10.7m13.6m25.8m
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Cash

111.6m322.3m249.6m285.4m224.4m215.9m401.6m382.3m333.4m660.5m

Accounts Receivable

48.8m51.6m51.8m68.2m90.8m94.4m115.5m77.0m90.1m93.8m

Prepaid Expenses

16.1m19.5m20.1m16.2m12.9m15.0m14.3m19.2m21.6m16.3m

Inventories

5.6m6.5m12.2m10.9m10.6m11.7m15.2m17.3m22.5m26.1m
Annual
EURFY, 2018FY, 2019FY, 2020FY, 2021

Net Income

84.1m37.2m6.3m215.5m

Depreciation and Amortization

31.4m50.1m56.2m70.4m

Inventories

(283.0k)(1.4m)(3.6m)(11.7m)

Accounts Payable

5.0m(2.0m)2.2m31.3m
Quarterly
EURQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021Q1, 2022

Net Income

13.1m10.7m29.7m17.1m7.3m5.8m52.7m112.7m247.0m(73.2m)
EURFY, 2018

Revenue/Employee

153.7k
Show all financial metrics

Evotec Operating Metrics

Evotec's Customers was reported to be 842 in FY, 2021. Evotec's New Customers was reported to be 337 in FY, 2021.
FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Products

80100100150130

Projects

4060608090

Customers

760707769829842

New Customers

611263283315337

Evotec Acquisitions / Subsidiaries

Company NameDateDeal Size
GlaxoSmithKine's the Verona siteJanuary 07, 2021
Just-Evotec BiologicsMay 20, 2019$90 m
AptuitJuly 30, 2017$300 m
CyprotexOctober 26, 2016£55.7 m
EuprotecMay 28, 2014$3.2 m
Bionamics GmbHMarch 24, 2014
Cell Culture Service GmbHJanuary 03, 2013€1.2 m
Compound FocusJune 01, 2011
KINAXO BiotechnologiesApril 19, 2011
Develogen AGJuly 14, 2010
Show more

Evotec Revenue Breakdown

Embed Graph

Evotec revenue breakdown by business segment: 76.2% from EVT EXECUTE and 23.8% from EVT INNOVATE

Evotec revenue breakdown by geographic segment: 7.6% from GERMANY, 16.9% from UNITED KINGDOM, 15.9% from REST OF WORLD, 54.6% from UNITED STATES and 4.9% from Other

Evotec Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

SecurityScorecard logo

Evotec Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Evotec Online and Social Media Presence

Embed Graph

Evotec News and Updates

Almirall and Evotec team up in multi-target dermatology alliance

The companies will focus on developing novel therapies for chronic skin diseases and skin cancer

Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a ‘Functional Cure’ for Diabetes

LONDON, Ontario, May 17, 2022 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE/XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell therapeutics, and Evotec SE (FSE: EVT; NASDAQ: EVO), a global pharmaceutical and life science company, and leading developer of…

Evotec SE fiscal year 2021 results: "Setting the Pace" on the data-driven R&D Autobahn to Cures

Group revenues significantly exceeded the revenue target, up 23% to € 618.0 m (+27% like for like, excluding portfolio and fx effects (2020: € 500.9 m)) Base business up 18% (20% adjusted for Sanofi payment in Q1 2020) Adjusted Group EBITDA in line with guidance at € 107.3 m, up 1% (2020: € 106.7 m)…

Evotec SE to announce results for fiscal year 2021 on 12 April 2022

The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. Conference call details Date: Time: 02.00 pm CEST (08.00 am EDT, 01.00 pm BST) To join the audio webcast and to access the presentation slides you will find a link on our homepag…

Evotec achieves programme designation in neuroscience collaboration with Bristol Myers Squibb

Induced pluripotent stem cells (also known as iPS cells or iPSCs) are a type of pluripotent stem cell that can be generated directly from adult cells. The iPSC technology was pioneered by Shinya Yamanaka’s lab in Kyoto, Japan, who showed in 2006 that the introduction of four specific genes encoding …

CMO Leadership Awards 2022

The awards are presented by Life Science Leader and Outsourced Pharma and the research is conducted by ISR Reports’ Contract Manufacturing Quality Benchmarking annual online surveys. “Congratulations to all the Life Science Leader and Outsourced Pharma 2022 CMO Leadership Award winners. An award in …
Show more

Evotec Frequently Asked Questions

  • When was Evotec founded?

    Evotec was founded in 1993.

  • Who are Evotec key executives?

    Evotec's key executives are Werner Lanthaler, Craig Johnstone and Enno Spillner.

  • How many employees does Evotec have?

    Evotec has 4,354 employees.

  • What is Evotec revenue?

    Latest Evotec annual revenue is €618 m.

  • What is Evotec revenue per employee?

    Latest Evotec revenue per employee is €141.9 k.

  • Who are Evotec competitors?

    Competitors of Evotec include Eurofins, WuXi Biologics and Actelion Pharmaceuticals.

  • Where is Evotec headquarters?

    Evotec headquarters is located at Essener Bogen 7, Hamburg.

  • Where are Evotec offices?

    Evotec has offices in Hamburg, Göttingen, Köln, Neuried and in 9 other locations.

  • How many offices does Evotec have?

    Evotec has 13 offices.